At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumours
In Brief
A Phase 2 clinical trial evaluating AZD0171, Durvalumab, and 2 other interventions for Locally Advanced or Metastatic Solid Tumours. Active but no longer recruiting, targeting 126 participants across 34 sites in 4 countries.
Signals
Detailed Summary
The proposed study is designed to examine the effects of AZD0171 and durvalumab in combination with standard-of-care chemotherapy in patients with pancreatic ductal adenocarcinoma (PDAC).
Study Details
Timeline
Arms & Interventions
Participants will receive AZD0171 (intravenous \[IV\]) along with durvalumab (IV) in combination with standard-of-care chemotherapy IV (gemcitabine and nab-paclitaxel).
Interventions
AZD0171
Durvalumab
Chemotherapy (Standard-of-Care)
Chemotherapy (Standard-of-Care)